Sign In
Buy PTCT
$68.01
-7.51 (-9.94%)
At Close: Jul 31, 2026
PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Friday, 31'st Jul 2026
Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall
PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript
09:53pm, Thursday, 30'th Jul 2026
PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript
PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates
06:26pm, Thursday, 30'th Jul 2026
PTC Therapeutics (PTCT) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.83 per share a year ago.
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
04:01pm, Thursday, 30'th Jul 2026
– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-yea
PTC Therapeutics, Inc. $PTCT Shares Purchased by Fifth Third Bancorp
04:05am, Saturday, 25'th Jul 2026
Fifth Third Bancorp increased its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 12,362.1% during the undefined quarter, according to the company in its most recent 13F filing with the
Hamilton Lane Board Elects Michael Schmertzler as New Independent Director
07:00am, Thursday, 23'rd Jul 2026
CONSHOHOCKEN, Pa., July 23, 2026 /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (Nasdaq: HLNE) announced that its Board of Directors elected Michael Schmertzler as a
PTC Therapeutics, Inc. $PTCT Shares Purchased by Bessemer Group Inc.
03:40am, Wednesday, 22'nd Jul 2026
Bessemer Group Inc. boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 21,814.1% in the undefined quarter, according to its most recent disclosure with the Securities and Excha
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
08:00am, Thursday, 16'th Jul 2026
WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial resul
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
07:28pm, Monday, 13'th Jul 2026
The transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options at $46.54 and their immediate sale at a weighted average price of $90.25. The disposition represent
Reasons Why Investors Should Consider Betting on PTC Stock Now
03:16pm, Friday, 10'th Jul 2026
PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs add new growth opportunities.
Stocks Look Shaky, But This Sector is Booming (Biotech)
02:06pm, Thursday, 09'th Jul 2026
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Wednesday, 08'th Jul 2026
PTC Therapeutics (PTCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
10:36am, Thursday, 02'nd Jul 2026
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
09:21am, Thursday, 18'th Jun 2026
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price incre
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 17'th Jun 2026
WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 1
